ORIGINAL RESEARCH article
Front. Neurol.
Sec. Headache and Neurogenic Pain
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1630720
This article is part of the Research TopicMigraine and comorbidities in childrenView all articles
Analysis and comparison of the trends in the burden of migraine in China and globally from 1990 to 2021, with a forecast to 2031
Provisionally accepted- 1First Affiliated Hospital of Chongqing Medical University, Chongqing, China
- 2Emergency Department, Guilin Hospital of the Second Xiangya Hospital CSU;, Guilin, China
- 3Department of Anesthesiology, Guilin Municipal Hospital of Traditional Chinese Medicine, Guilin, China
- 4Department of Anesthesiology, The First Affiliated Hospital of Guilin Medical University, Guilin, China, Guilin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Migraine is a prevalent neurological disorder in China and globally, imposing significant burdens on individuals and societies. The goal of this study was to characterize age-and sex-specific temporal patterns in migraine burden in China and worldwide from 1990 to 2021, focusing on incidence, prevalence, and disability-adjusted life years (DALYs). Methods This retrospective population-based study utilized data from the Global Burden of Disease (GBD) Study in 2021 to analyze the characteristics of migraine burden in China and globally. The study focused on changes in incidence, prevalence, and DALYs. Joinpoint analysis was employed to calculate the average annual percentage change (AAPC) and the corresponding 95% confidence interval (95% CI) to assess trends in the burden of migraine. The Autoregressive Integrated Moving Average (ARIMA) model was utilized to predict the migraine burden for the next decade. Results The worldwide age-standardized incidence rate (ASIR) of migraine rose from 1136.90/100,000 to 1153.20/100,000 between 1990 and 2021, whereas the ASIR in China grew from 917.35/100,000 to 975.61/100,000. Globally, the age-standardized prevalence rate (ASPR) rose from 14027.65/100,000 to 14246.55/100,000, while in China, it rose from 10948.52/100,000 to 11777.51/100,000. Female rates consistently exceed male rates across all age groups. Migraine incidence peaked in the 10–14 age group, while the prevalence and disability-adjusted life years (DALYs) peaked in the 30-34 age group for both females and males in 2021. The ARIMA model forecasts an upward trend in the ASIR and age-standardized DALYs rate (ASDR) for males in China over the next decade. Furthermore, the ASIR, ASDR, and ASPR for males globally, along with the ASIR and ASPR for females globally, are also anticipated to increase by 2031. Conclusion Our findings indicate a rising burden of migraine in China and globally. Females are more susceptible to migraine in all age groups. The burden of migraine is age-related, with adolescents and youths facing a higher risk. More research is needed to determine the risk factors and illness patterns linked to migraine to facilitate early diagnosis, prompt therapies, and lessen patient burden, especially for females and adolescents.
Keywords: Migraine, GBD 2021, Incidence, Prevalence, Disability-adjusted life years
Received: 18 May 2025; Accepted: 23 Sep 2025.
Copyright: © 2025 Tang, Tang, Li, Zhang, Qin and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wenjun Tang, tangwenjun56@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.